[Hypersensitivity to VM-26].
Life-threatening anaphylactic reactions to VM-26 are rare. In this report two patients with anaphylactic reactions after the first VM-26 applications in the German neuroblastoma therapy protocol GPO-NB-82 are described. After combination of VM-26 with dexamethasone, repetition of these reactions did not occur any more.
D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D006801:Humans; D009447:Neuroblastoma / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013713:Teniposide / Q000008:administration & dosage / Q000009:adverse effects*
D003907:Dexamethasone; D003520:Cyclophosphamide; D013713:Teniposide; D011034:Podophyllotoxin; D002945:Cisplatin
Uberempfindlichkeitsreaktion gegen VM-26.